[Report Code] IN050602

[Report Name] Indian Biopharmaceuticals Industry Report

[Date Published] 2006-2-1

[Number of Pages] 208

[Price: Electronic Version in  US$] 600

[Contact] 86-21-52395935 ext.2010 eChinaChem,Inc. Media Department  

[Abstract/Description of Report] 

Indian biotechnology industry is advancing into new heights in tandem with the growth and progression observed globally. The past performance of the industry indicates that it has surpassed the growth rate of many other industries. India is counted among the top 12 global biotech hotspots and is the 3rd largest in Asia Pacific (in terms of number of biotech companies). The global biotech industry size is currently US$54 billion, whereas the Indian biotech industry just crossed the US$1.07 billion (Rs4,745 crore) mark in 2004-05. Bio Pharma remained the largest contributor to the sector with a value contribution of Rs. 3,570 crore accounting for a 75% contribution. Diagnostics, vaccines and recombinant therapeutic proteins are the three main segments in bio pharma industry.

The report on Indian Biopharmaceuticals Industry covers the industry size and its growth over the past few years. The segments of the industry along with growth drivers and the issues and challenges of the industry are briefed. The core technologies in the industry and the major players of the industry are also discussed with their profiles. The regulatory environment and the associated bodies are mentioned and the critical success factors in the industry are highlighted. This report also has the details on emerging trends in the industry and the opportunities for India and to end the report an outlook for the industry is also given. The report will be useful to the biotech industry and especially companies in biopharma, agri-biotechnology, industrial biotechnology, bio-services and bioinformatics in understanding this industry in a better way. It will also be useful to the government department and agencies working in the field of biotechnology to get an insight of the biopharma industry. The educational institutes may also use this information for their academic purpose to have in -depth industry knowledge. Other research bodies, industry experts, associations & consortia of the industry and consulting organizations may also benefit through the information given in the report.

The report has been prepared from numerous sources which include: Publication of the industry, industry interactions, websites, and proprietary and subscribed databases. Due diligence and adequate care has been taken in the report to check and validate the figures used.

Total number of pages: 208, Number of tables: 23, Number of charts: 20

[Table of Contents]

Executive Summary

1. Industry Overview
1.1 The Industry, 1.1.1 Industry Structure, 1.1.2 Industry Size, 1.1.3 Industry Segments, 1.1.4 Segment Performance, 1.1.5 Exports Vs Domestic Business, 1.2 Introduction to Biopharma, 1.2.1 What is Biopharma?, 1.2.2 Industry Classification, 1.3 Biopharma Market Size, 1.4 Biopharma Industry Segments, 1.4.1 Vaccines, 1.4.2 Diagnostics, 1.4.3 Therapeutics, 1.5 Contribution of Biopharma sector to domestic & exports sales of Biotechnology

2. Segment Analysis – Biopharma
2.1 Segment Analysis: Vaccines, 2.1.1 An introduction to vaccines and vaccine trials, 2.1.2 Indian Vaccine Market Scenario, 2.1.3 Major Players, 2.1.4 Major Vaccines Available, 2.1.5 Challenges before the Vaccine Industry, 2.2 Segment Analysis: Diagnostics, 2.2.1 Diagnostics market Segmentation, 2.2.2 Current Market Scenario, 2.2.3 Demand Scenario, 2.2.4 Market is Import Driven, 2.2.5 Key Segments, 2.2.6 Major Players, 2.2.7 Emerging areas for diagnostic market, 2.2.8 Major Diagnostics, 2.2.9 India as a preferred destination for outsourcing clinical trials, 2.2.10 Challenges before the Indian Diagnostics Industry, 2.3 Segment Analysis: Therapeutics, 2.3.1 Current Market Scenario, 2.3.2 Major Therapeutic Segments, 2.3.3 Segment Analysis: Antibiotics Segment, 2.3.4 Demand for Recombinant Biotech Drugs In India, 2.3.5 Government Support for Recombinant Therapeutics, 2.3.6 Major Players, 2.3.7 Recombinant Therapeutic Products In India

3. Growth Drivers
3.1 Growing population and improving incomes, 3.2 Emerging lifestyle diseases, 3.3 Increasing Investment in Infrastructure and R&D, 3.4 Increasing Bio-partnering Activities, 3.5 Increasing Outsourcing Opportunities, Increasing Healthcare Expenditure, 3.6 Emerging Contract Research Market

4. Issues & Challenges
4.1 Increasing Productivity & Profitability, 4.2 Lack of Skilled manpower in the area of bio-pharma, 4.3 daunting regulatory system, 4.4 A Confusing Patent Law for India, 4.5 Ethical Issues, 4.6 FDA Regulations, 4.7 Environmental Factors, 4.8 Bioequivalence issue in Bio-generics, 4.9 Comparative Low R&D Expenditures Result in Price Wars, 4.10 Sub-Critical Resource Allocation by Public Companies, 4.11 High Duties on Imported Products Restrains Volume Growth, 4.12 Having Tailor-Made Drugs Could Result in Loss of Potential Revenues, 4.13 Small Biotech Start Ups Find Marketing of Products Difficult, 4.14 Access to capital, 4.15 Reducing Time to Market

5. Core Technologies in BioPharma
5.1 Antisense Technology, 5.2  Immobilization of enzymes and cells, 5.3 Cell culture, 5.4 Monoclonal Antibodies, 5.5 Protein engineering, 5.6 Biosensors, 5.7 Microarrays, 5.8 Enzyme engineering and Technology

6. Major Players
6.1 Biocon Ltd., 6.2 Serum Institute of India Ltd., 6.3 Panacea Biotech Ltd., 6.4 Aventis Pharma Limited, 6.5 Bharat Serums and Vaccines Ltd., 6.6 Glaxo SmithKline Pharmaceuticals Ltd., 6.7 Venkateshwara Hatcheries Private Ltd., 6.8 Chiron Behring Vaccines Private Ltd., 6.9 Indian Immunologicals Ltd., 6.10 Novo Nordisk

7. Regulatory Environment In Biopharma
7.1 Government of India Policy on Biotechnology, 7.2 Existing Regulatory Framework, 7.3 IPR Issues in Biotechnology, 7.4 Funding Agencies in Biotech Research, 7.5 Budgetary Allocation, 7.6 Venture Capital Funding, 7.7 Foreign Direct Investments, 7.8 National Biotech Development Strategy - 2005, 7.9 Sectoral Road Map from DBT on Biopharma, 7.10 Biopiracy, 7.11 Biosafety

8. Critical Success Factors
8.1 Human Resources, 8.2 Products, 8.3 Networking: Strategic Alliances & Partnering Activities, 8.4 Co-development, 8.5 Economies in R&D, 8.6 Developing New Therapeutic Segment, 8.7 Meeting the Global Demand, 8.8 World-class Practices

9. Emerging Trends
9.1 Big Pharmaceutical Companies Are Scouting For Biopharma Partners, 9.2 Increasing Demand for Biogenerics, 9.3 Companies Specialising In Specific Therapeutic or Disease Areas, 9.4 R&D Spend On the Rise, 9.5 Global Biotech R&D Productivity on the Rise, 9.6 Increasing Outsourcing by Pharmaceutical Companies, 9.7 Immunogenicity

10. Opportunities in India
10.1 Increasing Pharma R&D opportunities in India, 10.2 Opportunities in Clinical Research, 10.3 Increasing Opportunities in Contract Manufacturing

11. Outlook

Annexure I